USP24 stabilizes VDAC2 via deubiquitination to promote apoptosis and ferroptosis in clear cell renal cell carcinoma (ccRCC)
Open Access
- 8 September 2025
- journal article
- research article
- Published by Walter de Gruyter GmbH in Oncologie
- Vol. 27 (6) , 1029-1047
Abstract
Objectives: Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, and its pathogenesis is closely associated with dysregulated cell death. This study aims to elucidate the role of the ubiquitin-specific protease 24 (USP24) in ccRCC progression and its molecular mechanisms. Methods: Multi-omics data from the TCGA, GEO, and HPA databases were integrated to analyse USP24 expression levels and their clinical significance in ccRCC. The specific mechanism of interaction between USP24 and voltage-dependent anion channel 2 (VDAC2) was validated through co-immunoprecipitation, mass spectrometry analysis, molecular docking, and site-directed mutagenesis. In vitro functional assays – including deubiquitination assays, flow cytometry analysis of apoptosis, and assessment of ferroptosis-related markers – verified USP24’s inhibitory effect on ccRCC. Results: USP24 was significantly downregulated in ccRCC tissues and cell lines, with its low expression correlated with poor patient prognosis (hazard ratio [HR]=0.57, p<0.001), suggesting its potential utility as a prognostic indicator. Mechanistic studies revealed that USP24 directly binds VDAC2 and removes its ubiquitinylation at position 277, thereby stabilizing the VDAC2 protein. This stabilizing effect promotes apoptosis and ferroptosis in ccRCC cells, and reactivating this pathway may serve as a viable therapeutic strategy for ccRCC. Single-cell RNA sequencing analysis further confirmed the co-expression of USP24 and VDAC2 in renal tubular epithelial cells. Conclusions: This study reveals that the USP24-VDAC2 axis exerts key tumour-suppressive functions by promoting apoptosis and ferroptosis, thereby inhibiting ccRCC progression. Targeting this axis may provide novel therapeutic strategies for ccRCC.Keywords
Funding Information
- Weifang Science and Technology Development Plan Project (2025YX032)
- Natural Science Foundation of Shandong Province (ZR2024MH161)
- China Postdoctoral Science Foundation (2023M742311)
- The Innovation and Entrepreneurship Training Program for Students of Shandong Second Medical University (X2025035, X2025064 and X2025065)
This publication has 58 references indexed in Scilit:
- The Role of HADHB in Mitochondrial Fatty Acid Metabolism During Initiation of Metastasis in ccRCCMolecular Carcinogenesis, 2025
- First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose explorationAnnals of Oncology, 2024
- Comprehensive analyses of nuclear mitochondria‐related genes in the molecular features, immune infiltration, and drug sensitivity of clear cell renal cell carcinomaMedicine Advances, 2024
- USP24 promotes hepatocellular carcinoma tumorigenesis through deubiquitinating and stabilizing TRAF2Biochemical Pharmacology, 2024
- TRIM8 promotes ovarian cancer proliferation and migration by targeting VDAC2 for ubiquitination and degradationCancer Medicine, 2024
- Mechanistic engineering of celastrol liposomes induces ferroptosis and apoptosis by directly targeting VDAC2 in hepatocellular carcinomaAsian Journal of Pharmaceutical Sciences, 2023
- A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumorsCancer, 2019
- Systematic Expression Analysis of Mitochondrial Complex I Identifies NDUFS1 as a Biomarker in Clear-Cell Renal-Cell CarcinomaClinical Genitourinary Cancer, 2017
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular TumoursEuropean Urology, 2016
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012